Source-grounded facts extracted from NEOGENOMICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lynn A. Tetrault was appointed as Executive Chair at NEOGENOMICS INC.
“the Board appointed Lynn A. Tetrault, Esq. the Company’s non-executive Chair of the Board and Chair of the Culture and Compensation Committee, to serve as Executive Chair and the Company’s principal executive officer.”
Mark W. Mallon departed as Chief Executive Officer at NEOGENOMICS INC.
“On March 27, 2022, Mark W. Mallon, Chief Executive Officer (“CEO”) and a member of the Board of Directors (the “Board”) of NeoGenomics, Inc. (the “Company”), stepped down from his positions as CEO and director, effective as of March 28, 2022.”
David Sholehvar was appointed as President, Clinical Services Division at NEOGENOMICS INC.
“Dr. David Sholehvar, age 54, was appointed President, Clinical Services Division of the Company, effective March 14, 2022”
Steven Brodie was appointed as interim President of Lab Operations at NEOGENOMICS INC.
“Dr. Steven Brodie, the Company’s current Senior Vice President, Laboratory Operations, has been appointed the Company’s interim President of Lab Operations.”
George A. Cardoza departed as President and Chief Operating Officer, Laboratory Operations at NEOGENOMICS INC.
“George A. Cardoza, NeoGenomics, Inc.’s (the “Company”) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.”
Kevin Johnson resigned as Director at NEOGENOMICS INC.
“On January 17, 2022, Kevin Johnson provided NeoGenomics, Inc., a Nevada corporation (the “Company”), with notice of his resignation from the Board of Directors of the Company (the “Board”), effective as of January 17, 2022.”
Kathryn McKenzie was appointed as Chief Sustainability and Risk Officer at NEOGENOMICS INC.
“Kathryn McKenzie, the Company’s current Chief Financial Officer, was appointed Chief Sustainability and Risk Officer of the Company, also effective January 1, 2022.”
William Bonello was appointed as Chief Financial Officer at NEOGENOMICS INC.
“William Bonello, the Company’s current President, Informatics, was appointed Chief Financial Officer of the Company, effective January 1, 2022.”
Douglas VanOort resigned as Director at NEOGENOMICS INC.
“Effective today, Douglas VanOort has resigned from the Board.”
David Daly was appointed as Member of the Board at NEOGENOMICS INC.
“On November 4, 2021, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), voted to appoint David Daly to serve as a member of the Board, effective November 10, 2021.”
Lynn A. Tetrault was appointed as non-executive Chair of the Board at NEOGENOMICS INC.
“appointed Lynn A. Tetrault, the Company’s Lead Independent Director, as the non-executive Chair of the Board, effective October 7, 2021.”
Douglas M. VanOort resigned as Executive Chairman and Chairman of the Board at NEOGENOMICS INC.
“Douglas M. VanOort, the former Chief Executive Officer of NeoGenomics, Inc. (the “Company”) and currently the Company’s Executive Chairman and Chairman of the Board of Directors (the “Board”) of the Company, notified the Board of his voluntary decision to retire from the Company and that in connection with his retirement he was tendering his resignation as Executive Chairman and Chairman of the Board of the Company, effective October 7, 2021.”
Clive Morris was appointed as President of Inivata at NEOGENOMICS INC.
“in connection with Mr. Morris’s appointment as President of Inivata.”
Gina M. Wallar was appointed as President, Pharma Services Division at NEOGENOMICS INC.
“The Company announces that Dr. Gina M. Wallar, age 46, has been appointed President, Pharma Services Division effective July 5, 2021 to replace the vacancy left by Mr. Cardoza's assumption of his new position.”
George A. Cardoza was appointed as President and Chief Operating Officer, Lab Operations at NEOGENOMICS INC.
“NeoGenomics, Inc. (the “Company”) announces that George A. Cardoza, age 59, has been appointed President and Chief Operating Officer, Lab Operations effective July 5, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.